Barry Bonds TRT: How His Alleged Protocol Compares to Non-Celebrity Outcomes

What the BALCO Evidence Actually Said About Barry Bonds

The Bay Area Laboratory Co-operative (BALCO) investigation, launched by federal agents in 2003, produced grand jury testimony and physical evidence that Bonds used what prosecutors described as a stack of anabolic compounds. According to sealed grand jury transcripts later published by the San Francisco Chronicle, Bonds allegedly used testosterone (referred to as "the cream" and "the clear"), HGH, insulin, and trenbolone, a veterinary-grade androgen never approved by the FDA for human use [1].

"The Clear" and "The Cream"

"The clear" was later identified as tetrahydrogestrinone (THG), a designer anabolic steroid synthesized specifically to evade standard drug testing [2]. The FDA issued a public health advisory on THG in 2003, noting it had no approved medical use and carried unknown safety risks [3]. "The cream" contained testosterone and epitestosterone in a ratio formulated to suppress the urinary T/E ratio used in doping tests.

Neither compound has a therapeutic analog at the doses described. A clinician prescribing TRT would never reach for THG, it does not exist in any approved formulary.

HGH Allegations

Growth hormone was a second cornerstone of the alleged protocol. Recombinant human growth hormone (rhGH) is FDA-approved only for adult GH deficiency, short bowel syndrome, and HIV-associated wasting [4]. Using supraphysiologic rhGH in a healthy adult accelerates soft tissue growth, including acromegalic changes in the jaw, brow, and hands, physical changes widely noted by sports journalists covering Bonds between 1998 and 2003.

A 2006 review in the New England Journal of Medicine found that pharmacologic rhGH doses in healthy adults increased lean body mass by roughly 2 kg but produced no statistically significant strength gains, while tripling rates of soft tissue edema, arthralgias, and carpal tunnel syndrome [5].

Standard TRT in Hypogonadal Men: What the Clinical Data Show

Standard testosterone replacement therapy targets a serum total testosterone of 400 to 700 ng/dL, consistent with the Endocrine Society's 2018 clinical practice guideline, which recommends initiating TRT when total testosterone is confirmed below 300 ng/dL on two morning measurements with unambiguous symptoms of hypogonadism [6].

Lean Mass and Strength

A randomized controlled trial published in the New England Journal of Medicine (N=209 men aged 65 and older) showed that testosterone treatment for 12 months increased lean mass by a mean of 1.6 kg and leg press strength by 16% compared to placebo [7]. These are real, clinically meaningful changes, but they are categorically different from the 10 to 15 kg lean mass accrual reported anecdotally in elite athletes using supraphysiologic androgen stacks.

The Testosterone Trials (TTrials), a coordinated set of seven double-blind placebo-controlled trials published in JAMA and NEJM between 2016 and 2017, enrolled 790 men aged 65 or older with total testosterone below 275 ng/dL. Testosterone gel (1% AndroGel, titrated to 5 to 10 g/day) produced a mean increase of 83 points in IIEF-5 erectile function score and improvements in bone mineral density, but produced no significant benefit in cognitive function or cardiovascular events at 12 months [8].

Body Composition Timeline

In clinical practice, patients on therapeutic testosterone cypionate (typically 100 mg IM every 7 days or 50 mg every 3.5 days) see the following approximate timeline:

• Weeks 1 to 4: improved energy, libido, and morning erections
• Months 2 to 3: reduction in fat mass beginning in visceral depots
• Months 4 to 6: measurable lean mass gain (0.5 to 1.0 kg)
• Months 9 to 12: plateau effect; ongoing benefit requires resistance training

A 2013 Cochrane review of testosterone for older men (27 RCTs, N=2,994) confirmed that testosterone consistently reduced total fat mass and increased lean mass, but effect sizes were small to moderate (weighted mean difference for lean mass: 1.37 kg, 95% CI 0.97 to 1.77) [9].

What Does Not Happen With Therapeutic TRT

Patients on guideline-concordant TRT do not grow a hat size larger. They do not add 50 pounds of muscle after age 35. The acromegalic features, dramatic head and jaw changes, and sudden power surges observed in athletes credibly suspected of supraphysiologic hormone use reflect GH excess and androgen excess simultaneously, not replacement of a deficiency.

Supraphysiologic Androgens vs. Replacement: The Dose-Response Distinction

The distinction between replacement and abuse hinges on dose and target serum level. In a landmark NEJM dose-response study, Bhasin et al. (1996, N=61) assigned men to graded doses of testosterone enanthate from 25 mg to 600 mg weekly for 20 weeks, combined with or without a GnRH agonist to suppress endogenous production [10]. Fat-free mass increased linearly with dose: 25 mg produced essentially no change, while 600 mg weekly added a mean of 7.9 kg of fat-free mass, without any exercise intervention. The 600 mg arm also produced hematocrit increases, suppressed HDL by a mean of 9 mg/dL, and elevated LDL.

Standard TRT sits at the 50 to 100 mg weekly tier of that dose ladder. The alleged Bonds stack would occupy the far right tail, augmented further by HGH's additive anabolic signaling through IGF-1.

IGF-1 as the Amplifier

Growth hormone drives hepatic IGF-1 secretion, and IGF-1 is the primary mediator of skeletal muscle protein synthesis downstream of GH [11]. When supraphysiologic testosterone and supraphysiologic GH act simultaneously, their anabolic effects are not simply additive. A randomized trial by Sattler et al. (JAMA, 2009, N=262 men aged 65 to 90) tested GH plus testosterone vs. Either alone and found the combination produced significantly greater lean mass gain than either compound in isolation (P<0.001) [12]. That synergistic body composition effect explains the scale of physical transformation alleged in elite-level doping cases.

Cardiovascular and Oncologic Risks: Where Non-Celebrity Patients Should Pay Attention

The cardiovascular risk profile of supraphysiologic androgen use differs sharply from replacement therapy, and even replacement therapy carries risks that require monitoring.

Polycythemia

Testosterone stimulates erythropoiesis. The FDA's 2015 label update for all testosterone products added a warning about venous thromboembolism (VTE) [13]. In the TTrials cardiovascular sub-study, testosterone gel produced no significant increase in cardiovascular events, but hematocrit exceeded 54% in 7% of treated men, requiring dose reduction or phlebotomy. At supraphysiologic doses, erythrocytosis becomes severe enough to raise whole-blood viscosity to levels associated with stroke risk [14].

Prostate Safety

The Endocrine Society guideline explicitly states: "We recommend against starting testosterone therapy in patients with breast or prostate cancer" [6]. Long-term data on prostate-specific antigen (PSA) changes during TRT remain reassuring at replacement doses, a 2016 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found no significant PSA elevation beyond age-matched controls over 36 months [15]. The supraphysiologic range has not been studied in controlled trials for obvious ethical reasons.

Lipid Effects

Anabolic-androgenic steroids at bodybuilding doses consistently suppress HDL cholesterol by 20 to 50% and raise LDL [10]. Guideline-concordant TRT produces more modest lipid changes. A 2010 meta-analysis in Clinical Endocrinology found that physiologic testosterone replacement reduced total cholesterol modestly (mean change: minus 0.26 mmol/L) without consistent adverse effects on HDL [16].

Why This Comparison Matters for Non-Celebrity TRT Patients

Most men starting TRT are not former professional athletes. They are men in their 40s, 50s, or 60s with confirmed hypogonadism, total testosterone below 300 ng/dL, morning fatigue, reduced libido, and declining lean mass. For them, the relevant benchmark is not Barry Bonds's alleged transformation. The relevant benchmark is the TTrials.

The TTrials showed meaningful quality-of-life gains: sexual function improved in men with baseline testosterone below 275 ng/dL (P<0.001 for IIEF-5 score), bone mineral density in the lumbar spine increased by 7.5% over 12 months, and anemia resolved in 54% of treated men vs. 18% of placebo controls [8]. These are clinically significant outcomes for the target population.

Managing Expectations

Physicians at HealthRX see patients who arrive expecting Barry Bonds. They leave with a realistic protocol. A 52-year-old man with a total testosterone of 220 ng/dL, a BMI of 31, and moderate erectile dysfunction might expect, over 12 months of properly monitored TRT:

• Total testosterone rising to 450 to 600 ng/dL
• Lean mass increase of 1 to 2 kg (greater with structured resistance training)
• Fat mass decrease of 1 to 2 kg in visceral depots
• Improved IIEF-5 scores, though addressing vascular and psychogenic factors matters too
• Hematocrit monitoring every 3 to 6 months per Endocrine Society guidelines [6]

What he will not experience: acromegalic jaw changes, sudden 15-kg muscle gain, or the performance effects associated with supraphysiologic stacking. Those outcomes require illegal doses, compound combinations, and a tolerance for serious health risk.

The Legal and Safety Line

THG and trenbolone are Schedule III controlled substances under the Anabolic Steroid Control Act of 2004 [17]. Prescribing either for non-medical purposes carries federal criminal exposure. HGH prescribed outside its FDA-approved indications is similarly illegal under 21 U.S.C. § 333(e) [18]. Standard TRT, prescribed by a licensed clinician to a patient with documented hypogonadism and monitored against established labs, carries none of that legal exposure, and a well-characterized safety profile.

Monitoring Standards for TRT: The Clinical Protocol Non-Celebrities Actually Follow

Guideline-concordant TRT monitoring per the Endocrine Society (2018) includes [6]:

• Total testosterone at 3 months after initiation, then annually
• Hematocrit at baseline, 3 to 6 months, then annually
• PSA at baseline and 3 to 6 months in men over 40
• Bone mineral density at baseline in men with osteopenia or osteoporosis risk factors
• Lipid panel at baseline and 12 months

No monitoring protocol exists for supraphysiologic stacking because no protocol designed with patient safety in mind would permit those doses. The BALCO compounds were used with the opposite goal: maximizing performance at whatever physiologic cost, with doping evasion prioritized over health surveillance.

The Athletic Performance Gap: What Supraphysiologic Use Actually Buys

A 2008 systematic review in the British Journal of Sports Medicine examined 19 controlled studies of anabolic-androgenic steroids in athletes and found mean increases in maximal strength of 5 to 20%, with the largest effects in trained subjects using supraphysiologic doses (greater than 300 mg testosterone equivalent weekly) [19]. Lean mass gains in trained athletes at those doses averaged 4 to 11 kg over 10 to 20 weeks.

For context, the mean lean mass gain in the 600 mg testosterone enanthate arm of Bhasin 1996 was 7.9 kg over 20 weeks, and those subjects were sedentary [10]. Elite athletes adding structured training to supraphysiologic hormone stacks reach the upper end of that range.

Standard TRT in a 50-year-old hypogonadal man adds roughly 1.6 kg of lean mass over 12 months [7]. The performance gap between these two scenarios is not ambiguous. It is approximately five- to sevenfold in lean mass and corresponds to orders of magnitude in cardiovascular and hematologic risk.